European Regulatory Roundup, May 2022: IVDR Applies And MDR Critics Clamor Loudly For Action
Executive Summary
This is a landmark month with the expiry this week of the IVD Directive. May has also seen a flurry of new IVD guidance documents and some serious debates over hitches encountered in the implementation of the MDR and IVDR.
You may also be interested in...
Denmark Leads The Way On Speeding Up Approvals For Drug/IVD Combination Trials
While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.
Denmark Leads The Way On Speeding Up Approvals For Drug/IVD Combination Trials
While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.
EU Clarifies Requirements On Use Of Assays In The Context Of Clinical Trial Regulation
A new Q&A document clarifies the interface between the EU regulations on clinical trials and in vitro diagnostics to support the coordinated assessment of studies involving the use of diagnostic assays.